ALK and inflammatory myofibroblastic tumor: With the development of IMT recognition, the National Comprehensive Cancer Network (NCCN) Guidelines for Soft Tissue Sarcomas recommend first-generation ALK inhibitors as first-line treatment for IMT with ALK fusions, such as crizotinib, ceritinib, brigatinib, and lorlatinib.[10,13,23,24] Currently, there is no unified standard treatment for UIMT, and surgery, particularly total hysterectomy, is considered the best treatment.